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Elevated concentrations of tumor necrosis factor-a
(TNF-a) are detected in pathologies characterized
by chronic inflammation. Whether TNF-a plays
a role in manipulating the host’s immune system
toward generating an immunosuppressive milieu,
typical of ongoing chronic inflammation, is unclear.
Here we showed that TNF-a exhibited a dual function
during chronic inflammation: arresting differentiation
of immature myeloid-derived suppressor cells
(MDSCs) primarily via the S100A8 and S100A9
inflammatory proteins and their corresponding
receptor (RAGE) and augmentingMDSC suppressive
activity. These functions led to in vivo T and NK cell
dysfunction accompanied by T cell antigen receptor
z chain downregulation. Furthermore, administration
of etanercept (TNF-a antagonist) during early chronic
inflammatory stages reduced MDSCs’ suppressive
activity and enhanced their maturation into dendritic
cells andmacrophages, resulting in the restoration of
in vivo immune functions and recovery of z chain
expression. Thus, TNF has a fundamental role in
promoting an immunosuppressive environment
generated during chronic inflammation.
INTRODUCTION
Numerous pathologies, including cancer, infectious diseases,
and autoimmune disorders, are characterized by chronic inflam-
mation and an immunosuppressive environment, which leads to
T and natural killer (NK) cell dysfunction associated with T cell
receptor (TCR) z chain (CD247) downregulation. z chain is a key
component responsible for the initiation of immune responses
mediatedby these two cell types and is affectedby the generated
immunosuppressive milieu (Baniyash, 2004, 2006). Various
studies, including our own, have shown that chronic inflamma-
tion-dependent immunosuppression is mediated by myeloid-
derived suppressor cells (MDSCs), which represent a heteroge-
neous immature cell population of themyeloid lineage (Ezernitchi
et al., 2006; Vaknin et al., 2008). Expansion ofMDSCscoexpress-
ing Gr1+CD11b+ in mice and CD11b+CD14CD33+, LINHLA-DRCD33+, or CD14+CD11b+ in humans is observed in some of
the above-mentioned pathologies, resulting in suppression of
immune responses (Gabrilovich and Nagaraj, 2009; Ostrand-
Rosenberg and Sinha, 2009; Serafini et al., 2006).
Chronic inflammation is mediated by a complex network of
proinflammatory cytokines (IFN-g, IL-1b, IL-6), chemokines
(CXCL5, CCL2), and growth factors (GM-CSF, VEGF) persis-
tently secreted by normal self or modified cells including tumor
cells, thus affecting MDSC accumulation, activation, and
suppressive function (Bunt et al., 2006, 2007; Gallina et al.,
2006; Huang et al., 2007; Kusmartsev et al., 2008; Serafini
et al., 2004; Song et al., 2005; Yang et al., 2008). We previously
showed that elevated serum concentrations of the proinflamma-
tory cytokines IFN-g and TNF-a detected in chronically inflamed
mice correlate with extensive recruitment and expansion of
MDSCs (Vaknin et al., 2008). Although our studies indicated
that IFN-g plays a role in the initial stage of the developing inflam-
mation (Bronstein-Sitton et al., 2003), affecting generation and
recruitment of MDSCs, the role of TNF-a in MDSC-dependent
immunosuppression is, as yet, unknown.
TNF-a is a proinflammatory, multifunctional, and immunomo-
dulating cytokine (Pfeffer, 2003) that has been shown to be
harmful in various chronic pathologies such as rheumatoid
arthritis, psoriasis, type II diabetes, Crohn’s disease, and cancer
(Balkwill, 2006; Feldmann, 2002; Kopf et al., 2010; Reich et al.,
2005). Therefore, several FDA-approved TNF-a antagonists are
currently in clinical use for such pathologies (Cheng et al.,
2008). One of these antagonists, etanercept, a soluble form of
the TNF receptor (Goffe and Cather, 2003), has been shown to
be effective in treating patients with rheumatoid arthritis and
cancer (Friedberg et al., 2008; Scott, 2005; Wilson, 2008).
However, the mechanism by which TNF-a and accordingly its
antagonists regulate the host’s immune system during chronic
inflammation remains unclear. Our observations demonstrating
elevated amounts of TNF-a and MDSCs in chronically inflamed
mice in conjunction with the TNF-a characteristics led us to
suggest that TNF-a could play an important role in inducing
the immunosuppressive environment through MDSCs.
To test our hypothesis, we applied our previously described
in vivo mouse model system for chronic inflammation (Bron-
stein-Sitton et al., 2003; Vaknin et al., 2008) on Tnf/ and
Tnf+/+ (wild-type) mice and compared their immune competence
under the generated inflammatory conditions. Herein we demon-
strate that during chronic inflammation, TNF-a plays a key role in
manipulating the suppressive environment by controlling MDSCImmunity 38, 541–554, March 21, 2013 ª2013 Elsevier Inc. 541
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Figure 1. TNF-a Augments the Chronic Inflammatory Response
(A) A mouse model for chronic inflammation was established by repeated injections of heat-killed BCG bacteria; the mice were sacrificed at day +2, after the last
treatment.
(B)QuantitativePCRanalysis for TNF-amRNAexpression in isolatedMDSCs fromcontrol (noninflamed) andchronically inflamedTnf+/+mice, presentedas relative
quantification (RQ) compared to the expression in MDSCs from control mice, set as 1. Data of three experiments are presented (mean ± SEM, n = 3 per group).
(C) The weight of spleens was evaluated at day +2 after the third BCG injection.
(D and E) The percentage and absolute numbers of MDSCs (Gr-1+CD11b+) at day +2 after the last BCG treatment in the spleen (D) and bone marrow (BM) (E) are
presented. Results are representative of three or more independent experiments (error bars show SD, n = 4–7 per group).
*p < 0.03; **p < 0.005; ***p < 0.0001 (t test). See also Figure S1.
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TNF-a Supports MDSCs during Chronic Inflammationfeatures: arresting their maturation via the S100A8 and S100A9
proinflammatory proteins and their corresponding receptor,
RAGE, and enhancing intrinsic MDSC suppressive function by
increasing activity of both inducible nitric oxide synthase (iNOS)
and arginase 1, resulting in the elevation of reactive oxygen
species (ROS) production and NO. These lead to T and NK
cell in vivo dyfunctions associated with z chain downregulation,
a phenomenon that is reversible upon MDSC depletion. Finally,
treatment of mice during early stages of chronic inflammation
with etanercept leads to an increased maturation of MDSCs
into mature myeloid cells (dendritic cells and macrophages)
and reduction in their immunosuppressive activity, as reflected
by a retrieval of in vivo T and NK cell effector immune functions
and a recovery of z chain expression. Our results demonstrate542 Immunity 38, 541–554, March 21, 2013 ª2013 Elsevier Inc.a critical role of TNF-a in promoting a suppressive milieu during
chronic inflammation and highlight the underlying mechanisms.
RESULTS
TNF-a Is Involved in Enhanced MDSC Accumulation
Observed during Chronic Inflammation
Sustained exposure of mice to heat-killed pathogens or a single
Toll-like receptor (TLR) ligand leads to chronic inflammation as
reflected by accumulation of MDSCs and increased serum
amounts of IFN-g and TNF-a, as previously showed by us (Ezer-
nitchi et al., 2006; Vaknin et al., 2008). In addition, our initial anal-
yses depict that MDSCs isolated from chronically inflamed mice
(Figure 1A) display elevated TNF-a mRNA amounts (Figure 1B).
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major role in generating an immunosuppressive environment in
pathologies characterized by chronic inflammation (Gabrilovich
and Nagaraj, 2009; Kanterman et al., 2012; Ostrand-Rosenberg
and Sinha, 2009; Serafini et al., 2006) led us to hypothesize that
TNF-a under such conditions might affect MDSC accumulation.
To test this hypothesis, we first compared the response of Tnf+/+
and Tnf/ mice to a developing chronic inflammation, induced
by repeated heat-killed BCG injections (Figure 1A). The initial
results revealed that Tnf+/+ mice display a greater inflammatory
response, indicated by increased spleen weight (Figure 1C)
and size (data not shown) when compared to the Tnf/ mice.
Moreover, MDSC numbers in the spleen (Figure 1D) and bone
marrow (BM) (Figure 1E) of inflamed Tnf+/+ mice were signifi-
cantly elevated compared to those of inflamed Tnf/ mice. To
rule out the possibility that the decreased accumulation of
MDSCs observed in the Tnf/ mice was due to a general
reduced expression of proinflammatory cytokines such as
IFN-g, IL-1, and IL-6, previously shown to be involved in
MDSC accumulation (Bunt et al., 2006; Gallina et al., 2006; Song
et al., 2005), we assessed their expression in the spleen of in-
flamed Tnf+/+ and Tnf/ mice. Interestingly, in the absence of
TNF-a, the expression of IFN-g, IL-1, IL-6, and IL-12 were rather
upregulated (Figure S1A available online). However, the proin-
flammatory conditions generated in the absence of TNF-a could
not support MDSC accumulation, suggesting a unique role for
TNF-a. Further analysis of both inflamed Tnf+/+ and Tnf/ mice
revealed that MDSC distribution surrounding the spleen T cell
zoneswas not affected (Figure S1B) and that TNF-a had no effect
on the frequencyof the twomajorMDSCsubsets, thegranulocytic
(CD11b+Ly6G+Ly6Clo) and monocytic (CD11b+Ly6GLy6Chi)
subpopulations, both in the spleen and bone marrow (BM)
(Figure S1C), suggesting that TNF-a targets the whole MDSC
population. It is important to note that in all cases we excluded
the possibility of neutrophil (CD11b+Ly6G+) presence within the
MDSC population, because MDSCs were always positive for the
Ly6Cmarker, andcells expressingonly theCD11b+Ly6G+neutro-
phils markers were not detected (data not shown).
Further analyses revealed that percentages of regulatory
T cells (Treg cells; CD4+Foxp3+), reported as immunosuppres-
sive in various chronic pathologies (Vignali et al., 2008), were
not affected by TNF-a in the spleen and blood of inflamed
Tnf/ versus Tnf+/+ mice (Figure S1D).
TNF-a Negatively Affects T and NK Cell Functions
through MDSC Regulation
The observed reduced MDSC numbers in inflamed Tnf/ mice
suggests an improved immunological status. We therefore as-
sessed T and NK cell functions as well as z chain expression in
inflamed Tnf+/+ and Tnf/ mice. The results revealed that
whereas inflamed Tnf+/+ mice display a significantly reduced z
chain expression within T cells, inflamed Tnf/ mice show
elevated z chain expression (Figure 2A). In contrast, total amount
of CD3ε (Figure 2B) and the remaining TCR subunits (data not
shown) were similar in all experimental groups, indicating that z
chain is the sole TCR subunit affected by the developing chronic
inflammatory environment. Next we evaluated the in vivo impact
of MDSCs on z chain expression in T cells. We hypothesized that
MDSCdepletion could restore z chain expression in endogenous(host) immune cells as well as in newly administered (donor)
cells, mimicking adoptively transferred assays used today in
different immunotherapeutic regimens for various pathologies
(Huye and Dotti, 2010; Sutlu and Alici, 2009). Indeed, in vivo
depletion of MDSCs in inflamed Tnf+/+ mice (Figure S2)
completely restored z chain expression within the host T cells
as well as in the adoptively transferred CFSE-labeled T cells (Fig-
ure 2C), providing direct evidence of the in vivo effect of MDSCs
on z chain expression in T cells.
We next tested how lack of TNF-a affects T cell function during
developing chronic inflammation. We first compared the ex vivo
proliferation of splenic T cells from inflamed Tnf+/+ mice to those
of Tnf/mice in response to TCR-mediated activation. Although
T cells from inflamed Tnf+/+ mice displayed an impaired prolifer-
ative ability, T cells from inflamed Tnf/ mice were only slightly
affected (Figure 2D). Subsequently, we tested the ability of
T cells to proliferate in vivo in an antigen-specific manner. To
this end,micewere first immunizedwith a plasmid containing cy-
tomegaolovirus promoter, which ectopically expresses the gene
for ovalbumin (CMV-OVA). The mice were then subjected to the
treatment that induces chronic inflammation. At the peak of the
inflammatory response, evaluated by the high numbers of
MDSCs, mice were injected intravenously (i.v.) with CFSE-
labeled OT-I splenocytes (Figure 2E). Four days later the in vivo
proliferative response of CD8+ OT-I cells from the spleen of
immunized and nonimmunized mice was analyzed. As seen in
Figure 2F, only the CD8+ OT-I cells in the inflamed Tnf/ group
displayed a high proliferative response, and no proliferation was
detected in the cells from the inflamed Tnf+/+mice.Moreover, we
show evidence that the impaired proliferative response observed
in the spleen of Tnf+/+ inflamed mice was MDSC mediated,
because in vivo depletion of MDSCs completely restored the
ability of CD8+ OT-I cells to proliferate, in a similar manner as de-
tected in the noninflamed Tnf+/+ and Tnf/ immunized mice
(Figure 2F).
We next tested how absence of TNF-a affected NK cell func-
tions. First, z chain expression was analyzed in NK (NCR1+) cells,
because of its role in cell-mediated killing activity associated
with activating receptors such as NCR1 (Mao et al., 2010).
Although z chain expression was reduced in NK cells from
inflamed Tnf+/+ mice, its expression was hardly affected in
inflamed Tnf/ mice and was similar to that of the untreated
(control) mice of both groups (Figure 3A). In contrast, expression
of NCR1 (Figure 3B) was similar in all experimental groups,
indicating again that z chain is the sole subunit affected by the
developing inflammatory environment. Moreover, we also found
that the negative effect of TNF-a on z chain expression in both
host and adoptively transferred CFSE-labeled NK cells during
chronic inflammation was MDSC mediated, as shown by the
fact that in vivo depletion of MDSCs in inflamed Tnf+/+ mice
completely restored z chain expression in NK cells (Figure 3C).
To evaluate how the absence of TNF-a affected in vivo NK cell
cytotoxic function during chronic inflammation, we followed their
ability to clear allogeneic cells, as previously described (Oberg
et al., 2004; Vaknin et al., 2008). Mice were injected i.v. with
a mixture of labeled syngeneic (CFSEhi) and allogeneic (CFSElo)
cells, and after 24 hr the percentage of specific allogeneic cell
clearancewas evaluated (Figure 3D). To exclude the contribution
of other cells in the removal of allogeneic CFSE-labeled cells, weImmunity 38, 541–554, March 21, 2013 ª2013 Elsevier Inc. 543
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Figure 2. TNF-a Promotes T Cell Dysfunction via MDSCs
(A and B) Splenic CD3+ cells were fixed, permeabilized, and double stained for total expression of the z (A) or CD3ε (B) chains, as shown by mean fluorescence
intensity (MFI). z chain expression plots are of gated CD3+ cells.
(C) MDSCs were in vivo depleted in inflamed Tnf+/+ mice by three i.p. injections of Gr1 mAbs. 12 hr later, CFSE-labeled splenocytes from normal Tnf+/+ mice
(donor cells) were adoptively transferred into inflamed Gr1 mAb-treated and -untreated mice (hosts). After 24 hr, splenocytes were harvested and stained for z
expression (MFI) in CD3+ T cells within the CFSE+ (donor) or CFSE (host) cells.
(D) Splenocytes were labeled with CFSE and activated with CD3 and CD28 antibodies (black lines), or left nonactivated (gray histograms). The proliferative
response was assessed by monitoring cell divisions of gated CFSE-labeled Thy1.2+ cells.
(legend continued on next page)
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Figure 3. TNF-a Promotes NK Cell Dysfunction via MDSCs
(A and B) MFI of total z chain (A) and NCR1 (B) expression in NK (NCR1+) cells.
(C) z expression (MFI) was evaluated in NCR1+ NK cells CFSE+ (donor) or CFSE (host) cells, after MDSCs were in vivo depleted, as described in Figure 2C.
(D) CFSE-labeled allogeneic (CFSElo) and syngeneic (CFSEhi) cells were i.v. injected intomice 2 days after the last BCG injection. The cytotoxic activity of NK cells
was assessed 24 hr after administration of cells. Additionally, one group was depleted from MDSCs by Gr-1 mAbs.
(E) A representative plot of CFSE allogeneic and syngeneic cell clearance within the spleens of mice is shown (top); numbers indicate the percentages of specific
allogeneic cell clearance (bottom).
Results are representative of three or more independent experiments (error bars show SD, n = 4–6 per group). *p < 0.005 (t test). See also Figure S3.
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TNF-a Supports MDSCs during Chronic Inflammationdepleted NK cells in vivo, which resulted in almost a complete
retention of the allogeneic cells (data not shown). A significantly
impaired NK cell function in the spleen (Figure 3E) and blood
(Figure S3) of inflamed Tnf+/+ mice was observed, whereas NK
cell function in the inflamed Tnf/ mice was only slightly
affected. We also saw that impaired NK cell function in inflamed
Tnf+/+ mice is MDSC mediated, because in vivo depletion of(E) Mice were immunized with CMV-OVA plasmid and on day +2 after the last BCG
splenocytes into inflamed or noninflamed mice. Additionally, one group was trea
harvested to analyze the proliferation of the transferred OT-I CD8+ T cells by flow
(F) A representative plot gated on dividing OT-I CD8+ T cells in the spleens of infla
cells (bottom).
Results are representative of three independent experiments (error bars show SMDSCs completely restored NK cell cytotoxic function (Figures
3E and S3).
TNF-a Blocks MDSC Differentiation into Mature Myeloid
Cells
MDSCs are composed of a suppressive heterogeneous imma-
ture myeloid cell population that could differentiate into dendriticinjection the mice were adoptively transferred with 43 106 CFSE-labeled OT-I
ted for the depletion of MDSCs by Gr-1 mAbs. 4 days later, the spleens were
cytometry.
med and noninflamed mice (top); numbers indicate the percentage of dividing
D, n = 4–7 per group). **p < 0.005; ***p < 0.0001 (t test). See also Figure S2.
Immunity 38, 541–554, March 21, 2013 ª2013 Elsevier Inc. 545
Immunity
TNF-a Supports MDSCs during Chronic Inflammationcells (DCs) (CD11b+CD11c+) and macrophages (CD11b+F4/80+)
upon an appropriate stimulation (Gabrilovich andNagaraj, 2009).
Based on these data and on our results showing decreased
numbers of MDSCs in the spleens of inflamed Tnf/ mice (Fig-
ure 1D), we next checked whether mature myeloid cells such as
DCs and/or macrophages compensate for the reduced MDSC
numbers observed in the inflamed Tnf/ mice. Indeed, high
numbers of CD11c+ and F4/80+ cells were observed in the
spleens of inflamed Tnf/ mice, relative to those of inflamed
Tnf+/+ mice (Figure 4A). We also observed that the percentage
of MHC-II+CD80+ double-positive DCs and macrophages signif-
icantly increased in inflamed Tnf/mice, as compared to those
in the inflamed Tnf+/+ mice (Figure 4B), reflecting their increased
maturation stage toward antigen-presenting cells (APCs).
We next assessed whether the MDSC-intrinsic TNF-a expres-
sion directly affected their differentiation potential. To this end,
splenic MDSCs (CD11b+Gr-1+ cells) from inflamed Tnf+/+ and
Tnf/ mice (Figure S4A) were incubated with GM-CSF for 3 or
5 days and analyzed for cell phenotype changes. On day 0,
immediately after MDSC isolation, the percentages of CD11c+
and F4/80+ cells were similar between the Tnf+/+ and Tnf/
MDSCs. However, on days +3 and +5, Tnf/MDSCs displayed
a significantly greater differentiation capacity into CD11c+ and
F4/80+ cells as compared to Tnf+/+ MDSCs (Figure 4C). More-
over, the percentage of MHC-II+CD80+ double-positive DCs
and macrophages derived from the differentiated Tnf/ was
significantly increased as compared to those originating in the
Tnf+/+ mice (Figure 4D). Additionally, we also observed that
Tnf+/+ (Figure 4E) and Tnf/ (Figure S4B) MDSCs lost their
suppressive activity upon differentiation as reflected by their
inability to induce z chain downregulation when coincubated
with normal T cells as compared to nondifferentiated MDSCs.
Because previous studies have suggested that the S100A8
and S100A9 proinflammatory proteins are directly involved in in-
hibiting MDSC maturation through the NF-kB signaling pathway
(Cheng et al., 2008; Gebhardt et al., 2006; Sinha et al., 2008), we
tested the differences in S100A8 and S100A9 mRNA expression
between spleens of inflamed Tnf+/+ and Tnf/ mice. Spleno-
cytes derived from inflamed Tnf/mice expressed significantly
reduced S100A8 and S100A9 mRNA amounts relative to those
expressed in cells from inflamed Tnf+/+ mice (Figure 5A). More-
over, we also observed that freshly isolated MDSCs from in-
flamed Tnf/ mice had reduced endogenous S100A8 and
S100A9 mRNA (Figure 5B) and protein (Figures 5C and S5A)
expression relative to those that were detected in MDSCs from
inflamed Tnf+/+ mice. In addition, we also found that MDSCs
driven from inflamed Tnf/ mice expressed reduced protein
amounts of the RAGE receptor, which is the corresponding
receptor for the S100A8 and S100A9 proinflammatory proteins
(Figures 5C and S5A).
Finally, we assessed whether exogenous TNF-a could
reverse the increased maturation capacity of MDSCs isolated
from inflamed Tnf/ mice and whether its effect was mediated
via changes in the expression of the S100A8 and S100A9
proteins and RAGE. To this end, MDSCs isolated from inflamed
Tnf/ mice were incubated with GM-CSF in the presence or
absence of TNF-a for 3 days. On day +3, MDSCs incubated
in the presence of TNF-a showed an increased protein expres-
sion of both S100A8 and S100A9 and RAGE, as compared to546 Immunity 38, 541–554, March 21, 2013 ª2013 Elsevier Inc.MDSCs incubated in the absence of TNF-a (Figures 5D and
S5B). Based on our hypothesis that S100A8 and S100A9 and
RAGE blockade could abolish the negative effect of TNF-a,
we next evaluated the maturation state of MDSCs on day +5,
upon incubation with GM-CSF in the presence or absence of
TNF-a and RAGE- or S100A8- and S100A9-neutralizing anti-
bodies applied together or separately. On day +5, MDSCs
incubated with TNF-a show significantly reduced maturation
compared with that observed in MDSCs incubated with
GM-CSF only. Furthermore, we observed that incubation with
both RAGE-, S100A8-, and S100A9-neutralizing antibodies
fully restored the maturation of MDSCs treated with TNF-a,
as compared to MDSCs incubated only with GM-CSF (Fig-
ure 5E). We also observed that administration of both RAGE-,
S100A8-, and S100A9-neutralizing antibodies significantly
increased the maturation capacity of MDSCs treated only
with GM-CSF, reaching almost 100%. Similar results were
detected in MDSCs from inflamed Tnf+/+ mice (Figure S5C),
underlying the impact of exogenous TNF-a on the maturation
capacity of MDSCs mediated through S100A8 and S100A9
and RAGE.
TNF-a Enhances MDSC Suppressive Activity
To test the immunosuppressive function of MDSCs, we coincu-
bated MDSCs isolated from the spleens of inflamed Tnf+/+ and
Tnf/ mice at different ratios in relation to isolated T cells. We
observed that Tnf/ MDSCs displayed poor immunosuppres-
sive activity relative to Tnf+/+ MDSCs, as reflected by the induc-
tion of a milder z chain downregulation (Figure 6A) and a reduced
suppressive effect on T cell proliferation (Figures 6B and S6A),
suggesting that TNF-a affects not only MDSC differentiation
but also their state of activation.
It was previously demonstrated that TNF-a regulates the
activity of both iNOS and arginase 1 enzymes in endothelial
and malignant cell lines (Binder et al., 1999; Gao et al., 2007).
Because these enzymes are known to be involved in MDSC
suppressive activity, through the production of NO and ROS
and arginine deprivation (Bronte and Zanovello, 2005; Rodrı´-
guez and Ochoa, 2008), we evaluated their expression and
activity in MDSCs isolated from inflamed Tnf+/+ and Tnf/
mice. A significantly reduced iNOS mRNA (Figure 6C) and
protein (Figure 6D) expression were observed in Tnf/ MDSCs
as compared to that seen in Tnf+/+ MDSCs. In contrast, no
significant differences were observed between the groups in
arginase 1 expression (Figures 6C and 6D). However, evaluation
of ROS production (Figure 6E) and both iNOS (Figure 6F) and
arginase 1 (Figure 6G) activities revealed that the enzymes’
activity was significantly reduced in inflamed Tnf/ MDSCs
compared to that seen in Tnf+/+ MDSCs. Similar results were
observed in vivo when analyzing peripheral blood of inflamed
Tnf+/+ and Tnf/ mice. In this case, both inflamed Tnf+/+ and
Tnf/ mice had similar percentages of MDSCs (Figure S6B).
However, in the inflamed Tnf/ mice, the negative effect on z
chain expression was negligible as compared to that observed
in the inflamed Tnf+/+ mice (Figure S6C). Further analysis of
the peripheral blood MDSCs revealed that the suppressive
activity of MDSCs from Tnf/ mice was significantly reduced
as compared to that observed in Tnf+/+ mice, by showing
reduced ability to produce NO (Figure S6D) and ROS
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Figure 4. TNF-a Induces Arrest in MDSC Differentiation
(A) A profile of the percentage and absolute number of splenic CD11c+ and F4/80+ cells, gated on CD11b+ cells, in the spleen is presented.
(B) The expression of MHCII+CD80+ in CD11c+ and F4/80+ spleen-derived cells.
(C) MDSCs isolated from spleens of inflamed mice were cultured with GM-CSF for 3 and 5 days, and the cells’ phenotype was evaluated. Representative plots of
CD11c+CD11b+ (left) and F4/80+CD11b+ (middle) cells are shown; numbers indicate the percentages of differentiated cells (right).
(D) The percentage of MHCII+CD80+ double-positive CD11c+ and F4/80+ cells differentiated form spleen-derived MDSCs isolated from inflamed mice.
(E) MFI of z chain in normal isolated CD3+ T cells coincubated for 24 hr with differentiated MDSCs (treated with GM-CSF) or poorly differentiated MDSCs (treated
with BCGAg) from inflamed Tnf
+/+ mice at a 1:4 ratio. Before coincubation with the isolated T cells, MDSCs were cultured with GM-CSF (10 ng/ml) or BCG
(50 mg/ml) for 4 days.
Results are representative of three independent experiments (error bars show SD, n = 4–5 per group). *p < 0.02; **p < 0.005 (t test). See also Figure S4.
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Figure 5. TNF-a Blocks MDSC Maturation via S100A8 and S100A9 and RAGE Proteins
(A) S100A8 and S100A9 mRNA expression in splenocytes are shown relative to Tnf+/+ noninflamed mice, set as 1.
(B) S100A8 and S100A9 mRNA expression in isolated spleen-derived MDSCs is shown relative to Tnf+/+MDSCs (set as 1). Data of two independent experiments
are presented (mean ± SEM).
(C) S100A9, S100A8, and RAGE protein expression in splenic MDSCs isolated from inflamed mice were evaluated by immunoblotting. a-Tubulin served as
a control.
(D) S100A9, S100A8, and RAGE expression in splenic MDSCs isolated from inflamed Tnf/mice incubated with GM-CSF and TNF-a for 3 days were evaluated
by immunoblotting. a-Tubulin served as a control.
(E) MDSCs isolated from spleens of inflamed Tnf/mice were cultured with GM-CSF, TNF-a, RAGE antibody, and S100A8 and S100A9 antibodies (together or
separately) for 5 days, and cells’ phenotype was evaluated. Results are representative of two or more independent experiments (error bars show SD, n = 4–9 per
group).
*p < 0.01; **p < 0.002 (t test). See also Figure S5.
Immunity
TNF-a Supports MDSCs during Chronic Inflammation(Figure S6E). Taken together, these results indicate that TNF-a
affects also the suppressive activity of MDSCs.
In Vivo Blockade of TNF-a under Chronic Inflammatory
Conditions Modulates MDSCs and Restores Immune
Functions
Our final goal was to prove the direct in vivo TNF-a role in modu-
lating MDSC maturation and activity in Tnf+/+ mice exhibiting
chronic inflammation and to show that specific neutralization
of extracellular TNF-a restores immune functions. To this end,
we used the TNF-a antagonist etanercept and administrated it
daily, starting 1 day before the second BCG injection, when
the onset of MDSC accumulation was observed in the blood,
and continuing until 1 day before the mice were sacrificed (Fig-
ure 7A). Efficacy of etanercept treatment on inflamed Tnf+/+
mice was evaluated by comparing between their immune548 Immunity 38, 541–554, March 21, 2013 ª2013 Elsevier Inc.status and that of the inflamed Tnf/ mice. Reduced
spleen weight was observed in the inflamed etanercept-treated
Tnf+/+ mice compared with the etanercept-untreated inflamed
Tnf+/+ group (Figure S7A). Significant differences were also
observed in the accumulation of MDSCs in the spleen: the
etanercept-treated group showed a decreased percentage
(Figure 7B) and total numbers (Figure S7B) of splenic MDSCs.
Moreover, the reduced accumulation of MDSCs within the
etanercept-treated group was accompanied by a significant
increase in CD11b+CD11c+ and CD11b+F4/80+ cells within the
spleen (Figures 7C and S7C), indicating an etanercept effect
on MDSC maturation, similar to that observed in the inflamed
Tnf/ mice. Etanercept also had a significant effect on MDSC
activity, as reflected by their reduced production of NO (Fig-
ure S7D) and ROS (Figure S7E) in the inflamed etanercept-
treated group.
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Figure 6. TNF-a Enhances MDSC Suppressive Activity
(A) Purified normal CD3+ T cells were coincubated with isolated spleen-derivedMDSCs from inflamedmice at different ratios. After 16 hr, z chain expression (MFI)
in T cells was analyzed and compared to T cells incubated alone.
(B) CFSE-labeled CD3+ T cells activated with CD3 and CD28 antibodies were coincubated with isolated spleen-derived MDSCs from inflamed mice at different
ratios. Proliferation was assessed by monitoring cell divisions of gated CFSE-labeled Thy1.2+ cells after 72 hr and compared to CD3+ T cells activated alone.
(C) Analysis of iNOS and arginase 1mRNA in isolated spleen-derivedMDSCs from inflamedmice relative to the expression in Tnf+/+MDSCs (set as 1). Data of two
experiments are presented (mean ± SEM).
(D) Immunoblotting of iNOS and arginase 1 in isolated spleen-derived MDSCs from inflamed mice. a-Tubulin served as a control.
(E and F) Intracellular concentration of ROS (E) and NO (F) in spleen-derived MDSCs from inflamed mice were evaluated.
(G) Spleen-derived MDSCs isolated from inflamed mice were stimulated with BCG (50 mg/ml) for 48 hr. Cell lysates were collected and measured for arginase 1
activity. Results are representative of three independent experiments (error bars show SD, n = 4–5 per group).
*p < 0.02; **p < 0.005; ***p < 0.0003 (t test). See also Figure S6.
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TNF-a Supports MDSCs during Chronic InflammationWe next tested the effect of etanercept treatment on the
host’s immune status as well as on adoptively transferred T
and NK cells. We hypothesized that etanercept treatment, by
enabling MDSC maturation and reducing their suppressive
activity, could rescue the response of endogenous (host)
immune cells as well as of newly administered (donor) cells.
To this end, CFSE-labeled normal splenocytes were adminis-
tered i.v. at the peak of the inflammatory response (day +1)
and were harvested after 24 hr, thus mimicking cell mediated-
based therapies. Comparing z chain expression in donor
(CFSE+) and host (CFSE) T and NK cells localized in the spleen
of inflamed Tnf+/+ mice to those measured in control mice
revealed that etanercept administration to the inflamed Tnf+/+
mice significantly increased z chain expression in T (Figure 7D)and NK (Figure 7E) cells, both in the host and in the adoptively
transferred (donor) cells. Evaluation of etanercept effects on
in vivo NK and T cell function under chronic inflammatory
conditions showed reconstitution of both NK cell and T cell
activities. A significant elevation in the percentage of specific
allogeneic cell clearance was observed in the etanercept-
treated group compared to the etanercept-untreated group,
both in the spleen and blood (Figure 7F). Moreover, we also
found that etanercept treatment of inflamed Tnf+/+ mice
completely restored the ability of T cells to proliferate in vivo
as observed in the normal Tnf+/+ mice (Figure 7G). Taken
together, these results emphasize that in vivo blockade of
TNF-a leads to restoration of immune functions under chronic
inflammatory conditions by modulating MDSCs.Immunity 38, 541–554, March 21, 2013 ª2013 Elsevier Inc. 549
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Figure 7. Administration of Etanercept Modulates MDSCs and Restores Immune Functions
(A) WT mice were injected daily with etanercept from 1 day prior to the second BCG injection until 1 day before mice were sacrificed.
(B) The percentage of MDSCs in the spleen is presented.
(C) Percentage of CD11c+ and F4/80+ cells in spleens is presented; plots are gated on CD11b+ cells.
(D and E) CFSE-labeled splenocytes from normal Tnf+/+mice (donor cells) were adoptively transferred into mice (hosts). After 24 hr, splenocytes were harvested
and stained for z expression (MFI) in CD3+ T (D) and NCR1+ NK (E) cells within the CFSE+ (donor) or CFSE (host) cells.
(F) In vivo NK cytotoxicity assay was performed as described in Figure 3D. Allogeneic cell clearance in the spleen and blood are presented.
(G) In vivo T cell proliferation was performed as described in Figure 2E. A representative plot gated on dividing OT-I CD8+ T cells in the spleens (right); numbers
indicate the percentage of dividing cells (left).
Results are representative of two independent experiments (error bars show SD, n = 7 per group). *p < 0.02; **p < 0.003; ***p < 0.0005 (t test). See also Figure S7.
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TNF-a is a pleiotropic cytokine with both proinflammatory and
immunoregulatory functions, implicated in the development of
autoimmune diseases, chronic infections, and cancer, all char-
acterized by chronic inflammation and immunosuppression
(Balkwill, 2006; Feldmann, 2002; Kopf et al., 2010; Reich et al.,
2005). Although TNF-a has been unequivocally validated as
a therapeutic target in such immune-mediated inflammatory
disorders, the mechanism by which this cytokine manipulates
the host’s immune system toward the generation of a suppres-
sive environment remains unclear. A number of possible mech-
anisms for TNF-a-mediated immunosuppressive effects have
emerged, such as inducing lymphocyte apoptosis, inhibiting
TCR signaling and DC function, and activating Treg cells (Nagar
et al., 2010; O’Shea et al., 2002). However, the results are in
many cases complicated or controversial due to indications
that both timing and duration of TNF-a expression are important
in determining pathogenic versus protective roles.
Our results showing increased TNF-a concentration in the
serum (Vaknin et al., 2008) and elevated gene expression in
isolatedMDSCs from chronically inflamedmice led us to hypoth-
esize that TNF-a could play a role in inducing the immunosup-
pressive milieu observed during chronic inflammation. To test
our hypothesis, we applied our previously described in vivo
mouse model system for chronic inflammation, which mimics
the immunosuppressive conditions generated in the above-
mentioned chronic pathologies (Bronstein-Sitton et al., 2003;
Vaknin et al., 2008), on Tnf/ and Tnf+/+ mice and compared
their immune competence under the generated inflammatory
conditions. A follow-up of these mice revealed that TNF-a plays
a key role in inducing the immunosuppressive environment
generated during chronic inflammation by directly affecting
MDSCs in two ways: arresting their maturation and enhancing
their suppressive function. These lead to an impaired immune
status as reflected by T and NK cell in vivo dysfunction in asso-
ciation with z chain downregulation.
We have demonstrated that in the cell-mediated suppressive
milieu generated during chronic inflammation, MDSCs are the
cells primarily affected by TNF-a; although decreased MDSC
numbers were significantly observed in inflamed Tnf/ mice,
Treg cell numbers remained unchanged. The lack of TNF-a
also did not affect the relative distribution of the two major
MDSC granulocytic and monocytic subsets (Dietlin et al., 2007;
Youn et al., 2008), which were reported to differ in their function
during chronic infectious diseases and cancer. However, we
have demonstrated that lack of TNF-a affected MDSC matura-
tion, as reflected by the increased accumulation of both highly
mature macrophages and DCs in inflamed Tnf/ mice, indi-
cated by their double-positive MHC-II+CD80+ phenotype. We
also have shown that TNF-a directly affects MDSC maturation
ex vivo in response to GM-CSF stimulation; inflamed Tnf/
MDSCs display an increased ex vivo maturation capacity
compared to inflamed Tnf+/+ MDSCs. The enhanced MDSC
maturation in the inflamed Tnf/ mice was due to low expres-
sion of RAGE and its ligands, the S100A8 and S100A9 proteins;
although the increased maturation capacity of inflamed Tnf/
MDSCs was blocked upon incubation with exogenously added
TNF-a, an almost complete restoration of MDSC differentiationwas observed when using neutralizing antibodies for the RAGE
receptor and the S100A8 and S100A9 proinflammatory proteins.
Moreover, it was previously shown that TNF-a regulates in vitro
the expression of the S100A8 and S100A9 proteins in mouse
microvascular endothelial cells and macrophages (Xu and
Geczy, 2000; Yen et al., 1997), as well as of the corresponding
receptor, RAGE. Here we have demonstrated that indeed
TNF-a regulates both the expression of RAGE and S100A8 and
S100A9 mediators in MDSCs. Previous studies reported
S100A8 and S100A9 as proinflammatory mediators operating
in an autocrine feedback loop that sustains arrest of MDSC
maturation and enhances their accumulation (Cheng et al.,
2008; Sinha et al., 2008). However, these studies did not show
the TNF-a effect on the expression of these proteins in MDSCs.
Based on these and our observations, we suggest that during
chronic inflammation, TNF-a induces increased S100A8 and
S100A9 and RAGE production, which is associated with poor
MDSC differentiation into mature myeloid cells, conditions that
could be reversed by neutralizing TNF-a or blocking RAGE and
its ligands, the S100A8 and S100A9 proteins. Additional proin-
flammatory cytokines such as IL-1b, IL-6, and prostaglandin
E2 have been also described as mediating MDSC accumulation
at tumor sites, displaying characteristics of a chronic inflamma-
tory environment (Bunt et al., 2006, 2007; Sinha et al., 2007;
Song et al., 2005). Whether these cytokines affect MDSC differ-
entiation and S100A8 and S100A9 or RAGE expression in
concert with TNF-a will necessitate further studies.
Notably, TNF-a exhibits a broader effect on MDSCs, affecting
not only their maturation but also their suppressive function. A
significantly reduced production of ROS and activity of both
iNOS and arginase 1 was detected in MDSCs isolated from in-
flamed Tnf/mice compared to Tnf+/+mice, which was accom-
panied by reduced immunosuppressive activity as indicated by
elevated expression of z chain and the pronounced in vivo and
ex vivo T cell proliferation in response to activating stimuli and
NK cell cytotoxic function. We also show that the impaired
immune function of both T and NK cells observed during chronic
inflammation was mediated by MDSCs; upon their depletion,
a complete restoration of immune functions was achieved.
The direct in vivo role of TNF-a in promoting immunosuppres-
sion during a developing chronic inflammation was verified by its
neutralization by etanercept injection to WT mice at the onset of
the inflammatory response, where MDSC accumulation was
observed in the blood, mimicking etanercept’s therapeutic use.
Etanercept treatment restored the host’s immune function by
enhancing MDSC maturation into macrophages and DCs and
by abolishing their suppressive activity, resulting in the recovery
of z chain expression and elevated T and NK cell in vivo activity.
We demonstrated that the restored host’s immune system
features were similar between etanercept-treated inflamed
Tnf+/+mice and inflamed Tnf/mice, strengthening our conclu-
sion that TNF-a plays a key role in inducing an immunosuppres-
sive environment in the course of chronic inflammation. These
results obtained after etenarcept administration, which neutral-
ized the in vivo effects of extracellular TNF-a in inflamed WT
mice, and the effects observed in the ex vivo experiments where
MDSCs were subjected to exogenous TNF-a show that the main
role of TNF-a in the suppressive milieu is primarily mediated by
its extracellular appearance. However, whether intracellularImmunity 38, 541–554, March 21, 2013 ª2013 Elsevier Inc. 551
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an open question. Our data illuminate the mechanism underlying
the beneficial effect of anti-TNF-a treatments applied in various
diseases characterized by chronic inflammation and clarify the
basis for the effect of etanercept treatments as shown in mice
with colorectal carcinogenesis to reduce numbers of infiltrating
MDSCs and lessening tumor burden (Popivanova et al., 2008).
In conclusion, the results presented here provide an insight
into the relationship between TNF-a and the developing immu-
nosuppressive environment during chronic inflammation and
may aid in the generation of better therapeutic strategies against
various pathologies when elevated TNF-a and MDSC amounts
are detected.
EXPERIMENTAL PROCEDURES
Mice
Female C57BL/6 and BALB/c mice 6–8 weeks of age were purchased from
Harlan and were grown at the Hebrew University specific-pathogen-free
facility. Tnf-deficient mice on a C57BL/6 background were obtained from
the Jackson Laboratory and the OT-I mice on a C57BL/6 background were
a gift from the laboratory of A.-H. Hovav (Institute of Dental Sciences-The
Hebrew University of Jerusalem, Israel). Animal use followed protocols
approved by the Hebrew University-Hadassah Medical School Institutional
Animal Care and Use Committee.
The In Vivo Model System for Chronic Inflammation
Heat-killed Mycobacterium tuberculosis-BCG (231141; Difco Laboratories)
was administrated by three subcutaneous injections (50 mg per animal/dose)
at 1 week intervals to induce chronic inflammation. The first two injections
were administrated as a mixture of BCG and IFA (Sigma) at a 1:1 ratio, and
the third BCG injection was with PBS only. Unless stated otherwise, cells
were collected 2 days after the last injection (day +2). Control mice were sub-
jected to the same protocol, but injected with PBS only.
In Vivo Depletion of MDSCs
For depletion assay, 0.3 mg of Gr1 mAb (RB6-8C5) was intraperitoneally (i.p.)
administrated every 3 days into Tnf+/+ inflamed mice.
Etanercept Treatment
The TNF-a antagonist etanercept (Wyeth, UK) was administered daily (0.5 mg/
dose) by systemic i.p. injection starting from 1 day before the second BCG
injection until 1 day before cell harvest. Control mice were injected with PBS.
Flow Cytometry and Antibodies
Monoclonal antibodies specific for CD16 and CD32 (93; Biolegend) were used
for blockade of Fc receptors before staining. The antibodies used for cell
surface labeling were FITC-labeled anti-Gr-1 (RB6-8C5; Biolegend), anti-
CD11c (N418; Biolegend), anti-Ly6C (HK1.4; Biolegend), and anti-CD80 (16-
10A1; BD); phycoerythrin-labeled anti-Ly6G (1A8; Biolegend), anti-F4/80
(BM8; eBioscience), anti-CD3ε (145-2C11; Biolegend), and anti-mNKp46/
NCR1 (FAB2225P; R&D Systems); APC-labeled anti-CD45.1 (A20; Biolegend),
biotinylated anti-CD90.2 (30-H12; Biolegend), anti-CD11b (M1/70; Biolegend),
anti-MHC-II (KH74; Biolegend), and anti-CD4 (RM4-5; Biolegend); these were
detected by streptavidin-Cy5 (016-170-048; Jackson Immunoresearch). Intra-
cellular staining of z and CD3ε chains was performed as previously described
(Bronstein-Sitton et al., 2003). For Foxp3+ detection (3G3; Miltenyi Biotec),
a staining buffer set (eBioscience) was used according to the manufacturer’s
instructions. Samples were analyzed by FACSCalibur using Cell Quest soft-
ware (BD).
Immunohistochemistry
Paraffin-embedded spleen tissue sections were prepared from Tnf+/+ and
Tnf/ inflamed and uninflamed mice. After antigen retrieval, sections were
incubated at 4C with primary antibodies anti-CD3 (CD3-12; AbD Serotec)
and anti-Gr-1, (RB6-8C5; Biolegend). For immunohistochemical staining,552 Immunity 38, 541–554, March 21, 2013 ª2013 Elsevier Inc.universal immuno-peroxidase polymer for mouse tissues (414311F; Histofine)
was used, based on a horseradish peroxidase (HRP)-labeled polymer conju-
gated to anti-Rat. After incubation with anti-Rat for 30 min, slide staining
was completed by 3–5 min incubation with DAB+Chromogen (Lab Vision), fol-
lowed by counterstainingwith hematoxylin. As a control, samples were stained
with each antibody and reagent individually.
CFSE Staining and Ex Vivo Proliferation Assay
Splenocytes or purified T cells (20 3 106/ml) were incubated in PBS without
Ca2+ and Mg2+, containing 5 mM CFSE (Invitrogen) for 10 min at 37C; fetal
calf serum (FCS) was then added, and the cells were washed in RPMI+8%
FCS. CFSE-labeled cells were activated with 0.5 mg/ml of CD3ε (145-2C11;
Biolegend) and CD28 (37.51; Biolegend) antibodies. The number of cell divi-
sions of Thy1.2+ cells was determined by flow cytometry.
In Vivo NK Cell Cytotoxicity Assay
The in vivo cytotoxic activity of NK cells was determined as previously
described (Oberg et al., 2004). In brief, splenocytes from BALB/c and
C57BL/6 mice were stained with CFSE (Invitrogen), at final concentrations of
0.5 mM (CFSElo) and 5 mM (CFSEhi), respectively. Cells (5 3 1010) of each
type were mixed and injected into the tail vain of recipient C57BL/6 mice.
PBLs and spleen cells were harvested 24 hr postinjection and the ratio
between the CFSEhi and CFSElo cells was determined based on the flow cy-
tometry analysis. The percentage of specific allogeneic cell clearance was
calculated as described before (Vaknin et al., 2008).
In Vivo T Cell Proliferation Assay
The in vivo proliferation of T cells was performed as previously described (El-
nekave et al., 2010). In brief, mice were injected with 50 mg of CMV-OVA
plasmid into the ear pinna by a 31-gauge needle. Seven days later, chronic
inflammation was induced in some of the groups and at day +2, after the
last BCG injection, CFSE+ OT-I CD45.1+ splenocytes were i.v. injected into
the recipient CD45.2+ mice. Four days after the cell transfer, mice were sacri-
ficed and spleens were harvested. CFSE dilution were determined by flow cy-
tometry with CD8 and CD45.1 antibodies.
Cell Isolation and Separation
MDSCs and T cells fromcontrol or inflamedmicewere isolatedwith amagnetic
column separation system (Miltenyi Biotec), as previously described (Ezer-
nitchi et al., 2006), by performing two cycles of purifications, one with Gr1 anti-
bodies and a second one with CD11b antibodies. The purity of cell populations
was >95%.
MDSC Differentiation Assay
MDSCs were isolated from inflamed mice and cultured in the presence or
absence of 10 ng/ml GM-CSF (PeproTech) for 3 and 5 days. In some
experiments, 100 ng/ml of TNF-a (PeproTech) and a mixture of 10 mg/ml
of RAGE (AF1179; R&D Systems) and 20 mg/ml of S100A8 and S100A9
(AF3059 and AF2065; R&D Systems) neutralizing antibodies were added
to the cells, which were incubated with GM-CSF. After the different incu-
bation periods, cell phenotypes were determined by flow cytometry
analysis.
Quantitative PCR
Total RNA was recovered from splenocytes or isolated MDSCs by Tri-Reagent
(Sigma) and was subjected to reverse transcription with m-MLV-RT (Invitro-
gen) and random primers (IDT). Quantitative mRNA expression was analyzed
by real-time PCR (ABI 7900) with SYBR green (Invitrogen). RT-PCR primers
are listed in Table S1 and were designed to recognize an exon-exon boundary
in all transcripts.
Immunoblot Analysis
Proteins were extracted from isolated MDSCs (8 3 106) by standard tech-
niques. The following primary antibodies were used: iNOS (54/iNOS; BD
Transduction Laboratories), Arg1 (sc-18354; Santa Cruz), RAGE (AF1179;
R&D Systems), S100A9 (AF2065; R&D Systems), S100A8 (AF3059; R&D
Systems), and a Tubulin (sc-8035; Santa Cruz).
Immunity
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Arginase activity was measured in cell lysates from isolated MDSCs, as previ-
ously described (Corraliza et al., 1994). Urea concentration was measured at
540 nm with a microplate reader (Bio-Rad). Urea contents were calculated
based on a serially diluted urea standard curve.
NO– and ROS Measurements
iNOS activity was evaluated by measuring intracellular NO in Gr1+CD11b+
cells by using the DAF-2DA reagent (NOS 200-1; Cell Technology). ROS
production in Gr1+CD11b+ cells was performed by reactive oxygen species
detection kit (APF 4011; Cell Technology). In both cases, the detection of
NO and ROS was performed according to the manufacturer’s instructions
and was determined by flow cytometry analysis after staining.
Statistical Analysis
Student’s t test was used for statistical analysis. p values <0.05 were consid-
ered statistically significant.
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